
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
This is a compounded topical ointment containing cholestyramine resin, prepared to a prescriber's order for one patient. Compounded preparations are not FDA-approved.
These listings cover every salt or ester form of each drug in the FDA National Drug Code Directory.
FDA-approved products containing cholestyramine are listed in powder for suspension and powder forms. No finished cholestyramine product of any kind is listed in ointment form.
Bases for this dose form are usually nonaqueous. Under USP <795>, nonaqueous preparations carry longer default beyond-use dates than water-containing ones. The date printed on the label is the one to follow.
Compounded drugs are not FDA-approved. This means that FDA does not review these drugs to evaluate their safety, effectiveness, or quality before they reach patients.
Cholestyramine is a bile acid binding resin that compounding pharmacies prepare by prescription as topical ointments and flavored or sweetener-free oral suspensions.
Cholestyramine is a bile acid sequestrant, a positively charged resin that is not digested or absorbed. In the intestine it binds bile acids into an insoluble complex that leaves the body in the stool, so the liver pulls cholesterol from the blood to make more bile acids. Manufactured cholestyramine powder for oral suspension is FDA-approved as an adjunct to diet for primary hypercholesterolemia and for the relief of itching caused by partial biliary obstruction. Because bile acids in stool can irritate skin, the same binding action has been described when the resin is applied topically. A prescriber might order compounded cholestyramine when a patient needs a topical ointment, which is not manufactured, or an oral preparation without the aspartame, sugar or flavor in the commercial powder. Compounded preparations are not FDA-approved and require a prescription.
Cholestyramine has no boxed warning. Its main problem is constipation, which can progress to fecal impaction and worsen hemorrhoids, especially in people over 60; bloating, gas, nausea and heartburn are common. Rare intestinal obstruction has been reported in children. Long-term use can lower absorption of vitamins A, D, E and K and folate, with bleeding risk from vitamin K deficiency, and prolonged use in small children can cause hyperchloremic acidosis. Call your prescriber for unusual bleeding. The resin binds many other medicines, including warfarin, digoxin, thyroid hormone, thiazide diuretics, propranolol, tetracycline, penicillin G, phenobarbital, estrogens and progestins, so take other oral drugs at least 1 hour before or 4 to 6 hours after it. It must not be used with complete biliary obstruction. The manufactured light powder contains phenylalanine, which matters in phenylketonuria. Pregnancy is category C because of reduced vitamin absorption; LactMed considers it acceptable during breastfeeding since it is not absorbed. For side effects, talk to your prescriber or pharmacist.
Cholestyramine is a non-absorbable anion exchange resin that binds intestinal bile acids, interrupting enterohepatic recirculation, up-regulating hepatic bile acid synthesis from cholesterol and lowering LDL-C. There is no systemic absorption and therefore no meaningful half-life or protein binding; its clinical effects and interactions occur within the gut lumen. Labeled indications: cholestyramine for oral suspension USP (Epic Pharma and other generic labelers) as an adjunct to diet in primary hypercholesterolemia and for pruritus of partial biliary obstruction. Prescribers have ordered compounded topical cholestyramine ointment for perianal skin irritation after ileoanal anastomosis (Møller et al., 1987) and for an infant's buttock rash resistant to standard therapy (White et al., 2002), and bile acid sequestrants have been proposed for diarrhea from bile acid malabsorption (Scaldaferri et al., 2013), all off-label. Dosing, vehicle and application frequency are per prescriber. Monitor fat-soluble vitamin status, folate and INR with long-term oral use, chloride and acid-base status in small children, and bowel function; when a drug such as digoxin was titrated during resin therapy, stopping the resin can raise its levels. Separate all oral co-medications by the labeled interval. Cholestyramine is not a controlled substance.
Wash your hands. Apply a thin layer to the affected area and rub in gently as your label directs. Do not cover with a bandage or wrap unless your prescriber tells you to. Keep it out of your eyes. Do not apply to open wounds or broken skin unless told to. Wash your hands after applying.
Ointments are usually nonaqueous, so a USP <795> default beyond-use date of up to 180 days may apply when no other data exist. Store in the closed container at room temperature, away from heat and direct light, keep from freezing, and keep out of reach of children. Discard after the beyond-use date on the label.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Apply topically to affected area(s)